Porton Pharma Solutions: Investor Relations Activity Schedule for April 28, 2024
Porton Pharma Solutions: Independent Director's 2023 Debriefing Report (Pang Jinwei)
Porton Pharma Solutions: Special Report on the Deposit and Use of Funds Raised in 2023
Porton Pharma Solutions: Announcement on the launch of foreign exchange derivatives trading business for hedging purposes in 2024
Porton Pharma Solutions: 2023 Internal Control Self-Assessment Report
Porton Pharma Solutions: Internal Control Management System (April 2024)
Porton Pharma Solutions: Announcement on holding an online results briefing for 2023 and the first quarter of 2024
Porton Pharma Solutions: Announcement on the renewal of the 2024 Audit Institution
Porton Pharma Solutions: Supervisory Board's Verification Opinions on Termination of Implementation of the 2021 Restricted Stock Incentive Plan and Restricted Stock Repurchase and Cancellation
Porton Pharma Solutions: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Porton Pharma Solutions: Independent Director's 2023 Debriefing Report (Cao Guohua)
Porton Pharma Solutions: Legal opinion of Beijing Wanshang Tianqin Law Firm on the termination of implementation of the 2021 Restricted Stock Incentive Plan by Chongqing Boteng Pharmaceutical Technology Co., Ltd. and the repurchase and cancellation of restricted stocks related to
Porton Pharma Solutions: The Board's special opinion on the sole director's independence assessment
Porton Pharma Solutions: Information Disclosure System (April 2024)
Porton Pharma Solutions: 2023 Annual Audit Report
Porton Pharma Solutions: Announcement on preparation for impairment of assets accrued in 2023 and scrapping of some assets
Porton Pharma Solutions: CITIC Securities Co., Ltd.'s special inspection report on the storage and use of funds raised by Chongqing Boteng Pharmaceutical Technology Co., Ltd. in 2023
Porton Pharma Solutions: Announcement of Board Resolutions
Porton Pharma Solutions: 2023 Environmental, Social and Governance Report
Porton Pharma Solutions: 2024 First Quarter Report
No Data